Africa & Middle East
ResMed’s executive team is committed to the highest standards of ethics and professional integrity, translating to great partnerships with our customers, our suppliers, and with our global ResMed team. Our friendly, smart and dynamic executive team is dedicated to providing the right solutions with the right results, every time.
Michael “Mick” Farrell is the CEO for ResMed and has held the role since March 2013. Prior to that appointment, Mr. Farrell served as President, Americas for ResMed from 2011 to 2013. He was previously senior vice president of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development at the company.
Before joining ResMed in 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals, and metals manufacturing at Arthur D. Little, Genzyme Corporation (now part of Sanofi), The Dow Chemical Company, and BHP Billiton.
Mr. Farrell serves on the board of directors of Zimmer Biomet (NYSE: ZBH), a multi-billion dollar public company that provides implantable musculoskeletal medical devices for patients globally. Mr. Farrell is a member of the Compensation and Management Development committee as well as the Research, Innovation and Technology committee at Zimmer Biomet. Mr. Farrell serves on the ResMed board of directors as well as on the board of directors of the Advanced Medical Technology Association (AdvaMed), based in Washington, DC. Mr. Farrell volunteers as a trustee for two non-profit organizations, the La Jolla Playhouse and the Museum of Man, in his home town of San Diego, California.
Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management.
Robert Douglas added president to his role of chief operating officer in March 2013 and, together with ResMed chief executive officer, Mick Farrell, holds full operational responsibility for ResMed and its subsidiaries. Mr. Douglas has served as chief operating officer since September 2011. His former roles with the company include chief operating officer of Asia Pacific and global supply chain from June 2008 through September 2011, responsible for the region’s commercial distribution and sales operations, as well as global manufacturing; Sydney chief operating officer from November 2005 through June 2008, responsible for the company’s manufacturing and research and development; vice president of operations from 2003 to 2005, responsible for the company’s manufacturing; and vice president of ResMed’s respiratory and cardiac business from 2002 to 2003.
Mr. Douglas first joined ResMed in 2001 as vice president of corporate marketing.
Mr. Douglas has a Master of Business Administration from Macquarie University, a Bachelor’s degree in electrical engineering with first-class honors, and a Bachelor of Science in computer sciences from the University of New South Wales, Sydney.
Brett Sandercock has been chief financial officer since January 2006. Previously, he served as vice president of Treasury and Finance from November 2004 until December 2005, and group accountant and controller from 1998 to November 2004.
Before joining ResMed, Mr. Sandercock he was manager of Financial Accounting and Group Reporting at Norton Abrasives, a division of the French multi-national, Saint Gobain, from March 1996 to August 1998. He also held finance and accounting roles from November 1994 to March 1996 at Health Care of Australia, a large private hospital operator. From 1989 to 1994, he worked at Pricewaterhouse Coopers in Sydney, specializing in audits of clients predominantly focused on distribution and manufacturing, financial services and technology.
Mr. Sandercock holds a Bachelor of Economics from Macquarie University and is a Certified Chartered Accountant.
David Pendarvis was appointed interim President for EMEA and Japan in March 2017. He has served as both Chief Administrative Officer and Global General Counsel since May 2011. Mr. Pendarvis joined ResMed as global general counsel in September 2002, and has been corporate secretary since February 2003. From February 2005 to May 2011, he served as senior vice president of Organizational Development.
Before joining ResMed, Mr. Pendarvis was a partner in the law firm of Gray Cary Ware & Freidenrich LLP from September 2000 until September 2002, where he specialized in intellectual property and general business litigation. From 1986 to 2000, he was a partner with Gibson, Dunn & Crutcher LLP. From 1984 to 1986, he was a law clerk to the Hon. J. Lawrence Irving, U.S. District Judge, Southern District of California. He is also a director on the Board of Sequenom, Inc.
Mr. Pendarvis holds a Bachelor of Arts from Rice University; a Juris Doctor (J.D.), cum laude, from the University of Texas School of Law; and a Master of Science in Executive Leadership from the University of San Diego.
Greg Peake became president of ResMed’s Sleep-Disordered Breathing and Consumer Global Business Unit in December 2014. Previously, Mr. Peake was director of Global Product Marketing–Devices in the Sleep-Disordered Breathing Strategic Business Unit since August 2013, and director of Global Product Marketing–Patient Interfaces since February 2012.
Prior to that, Mr. Peake held several roles in product marketing, both in Sydney and San Diego, California, from 2009 to 2012. He joined ResMed in 2005, working as a design engineer in Research & Technology before joining the Global Marketing team in 2007. Prior to ResMed, Mr. Peake worked as a design engineer at Electrolux Home Products, Pty Ltd, and is identified as an inventor or co-inventor on numerous patents granted worldwide.
Mr. Peake holds a Bachelor of Engineering degree with honors in mechatronics and a Master of Science in industrial design from the University of New South Wales.
Luke Maguire became president of ResMed’s Cardio–Respiratory Care Global Business Unit in December 2014. Previously, Mr. Maguire was senior director of Human Resources for ResMed’s Global Sleep-Disordered Breathing Strategic Business Unit from 2013 to 2014 and senior director of Healthcare Informatics from 2011 to 2013, based in ResMed’s San Diego headquarters. Prior to that appointment, he led several product management teams within the company, including the launch of the S9™ flow generator platform in 2009. Prior to joining ResMed in 2004, Mr. Maguire worked in various design and engineering roles in the automotive industry.
Mr. Maguire holds a Bachelor of Engineering in mechanical engineering and a Ph.D. in engineering from the University of New South Wales.
Raj Sodhi became president of ResMed’s Healthcare Informatics Global Business Unit in December 2014. He was previously vice president of the global Healthcare Informatics team, helping to build strength in this critical function for the company. Mr. Sodhi joined ResMed through the acquisition of Umbian Inc. in July 2012 where he was co-founder and president.
Prior to this, Mr. Sodhi worked in the financial services industry, designing, developing and managing software as a service (SaaS) solutions: He was senior vice president of Business Development and chief technology officer for Skipjack Financial Services from 2005 to 2009, and co-founder and chief technology officer of TransActive Ecommerce Solutions from 2000 to 2005.
Mr. Sodhi holds a Master of Business Administration and a Bachelor of Science in mathematics and statistics from Dalhousie University.
Jim Hollingshead was appointed president of ResMed’s Americas region in March 2013. He joined the company in March 2010 as vice president of strategy and business development. In August 2011, his role was expanded to include the leadership of ResMed ventures and initiatives, the unit within ResMed responsible for growing early-stage businesses.
Before joining ResMed, Mr. Hollingshead spent 18 years in strategy consulting, where he worked with senior executives across a wide range of industries. From September 2008 to February 2010, he was a senior partner in the strategy and life sciences practices at Deloitte Consulting, based in San Francisco. Before that, he was West Coast managing partner for Monitor Group, a leading global strategy consulting firm. While at Monitor Group, Mr. Hollingshead worked in various offices around the world and successfully launched and ran three different practices, including a London-based pan-European marketing strategy practice.
Mr. Hollingshead holds a Bachelor of Arts in history and international relations with Highest Distinction from Stanford University, and a master’s and Ph.D. in political science from the University of California at Berkeley, where he was awarded a graduate student Fellowship by the National Science Foundation.
Katrin Pucknat was appointed Chief Executive Officer of ResMed Healthcare, Germany during July 2016. ResMed Healthcare is a German homecare provider which services patients with sleep-disordered breathing, COPD and other chronic respiratory diseases.
Ms. Pucknat joined ResMed in 2010 and has served in a variety of senior roles. Immediately prior to her current role, Katrin served as vice president of business transformation and had responsibility within ResMed Healthcare for patient services, TPR, field offices and the consumer business. Prior to that role, she was the director of marketing for ResMed’s sleep-disordered breathing business in Europe.
Before joining ResMed, Ms. Pucknat held various senior executive global marketing roles in the United States and Europe. She has almost 20 years of experience in the medical device segment, with particular focus on the functions of marketing, communications, business innovation and business development.
While gaining her broad experience based in the U.S. market, Ms. Pucknat earned a Bachelor of Business and Marketing degree from the University of Phoenix. She is based at the headquarters of our ResMed Healthcare business in Munich, Germany.
Justin Leong became senior vice president of ResMed’s growth markets in Asia, including China and India, in May 2016. He was previously general manager of Greater China from 2015 to 2016, and vice president of Global Strategy from 2013 to 2016, based in Sydney.
Prior to joining ResMed, Mr. Leong was a director of the London-based investment firm HgCapital from 2006 to 2012. In this role, Mr. Leong was responsible for acquisitions and portfolio management, and he served on the board of directors of several European healthcare companies. From 1999 to 2004, Mr. Leong was a management consultant with Bain & Co. in Sydney, Boston and New York where he advised clients on growth strategies, operational improvement projects and mergers & acquisitions.
Mr. Leong holds a Bachelor of Commerce and Bachelor of Laws from the University of New South Wales, and an M.B.A. from Harvard Business School.
Frank Lacagnina joined ResMed in September 2010, and as a member of the CEO Ops team, he helps develop corporate strategy while leading a diverse and globally positioned information technology organization.
Over the past 30 years, Mr. Lacagnina has led IT organizations within semiconductor and medical device manufacturing, financial, government and health insurance businesses. Prior to ResMed he spent 14 years introducing innovative technical business solutions for Motorola’s Semiconductor Product Sector (SPS) and at the Motorola spin-off company ON Semiconductor. He also was the CIO for a sovereign Indian nation in Scottsdale, Arizona, developing people and leveraging the latest technologies to drive significant advancement and modernization for the community, including public safety, justice administration, patient management and other critical services and systems.
Mr. Lacagnina specializes in the leadership of global IT organizations, with a focus on turnaround, digitalization and efficiency. He holds a Bachelor of Business Administration from the University of Arizona, majoring in Management of Information Systems. He also earned an Associate of Applied Sciences degree in computer programming/analysis from Pima Community College in Tucson, Arizona. He has completed further studies in leadership and management from the Thunderbird International School of Business and the W.P. Cary Business College at Arizona State University.
Richie McHale was appointed Chief Human Resources Officer in November 2013 and is responsible for linking ResMed’s employee and corporate strategies. Mr. McHale has 25 years’ experience in the life sciences sector, working primarily in commercial roles in pharmaceutical, biotechnology and medical technology industries. Previously, he served as managing director of ResMed’s UK business team, leading strong growth in the region.
Prior to joining ResMed in 2011, Mr. McHale was managing director of UCB Pharma for UK and Ireland. He also served as chair of the European Medicines Group and a member of the Board of Management for the Association of British Pharmaceutical Industry (ABPI).
Mr. McHale earned a Master’s degree in coaching psychology and is affiliated with the British Psychological Society and the Metanoia Institute in London.
Dr. Carlos Nunez M.D. was appointed Chief Medical Officer in January 2017. Prior to joining ResMed, Dr. Nunez was senior vice president of medical affairs at Becton, Dickinson and Company and led the office of science, medicine and technology for its largest division. Before that, Dr. Nunez was chief medical officer at CareFusion, where he built and led a global team which provided medical oversight for all businesses and functions of the company.
From 2000 to 2011, he was the Chief Physician Executive at Picis, Inc., an industry-leading medical informatics company, which became part of the Optum division of UnitedHealth Group. At Picis/Optum, Carlos provided medical leadership as well as clinical direction for corporate strategy, marketing, product development, sales, implementation and customer relations for global markets.
Dr. Nunez received his Medical Doctor (M.D.) degree from the University of Miami School of Medicine, where he also completed his postgraduate training in anaesthesiology, critical care medicine and clinical research.
Before beginning his career in the MedTech industry, Carlos was a practicing anaesthesiologist; intensivist and hospitalist; director of critical care research, informatics and analytics; and the Duke University educational affiliation at Carolinas Medical Center Northeast.
Andrew Price was appointed President of ResMed’s Innovation and Operations in March 2016. Previously Mr. Price was Senior Vice President, Global Manufacturing and Logistics. Prior to this he was Vice President of Marketing for Asia Pacific and Vice President of Product Development and Marketing in the company’s Sleep Disordered Breathing business unit.
In nearly 17 years with ResMed, Mr. Price has held a broad variety of global and Asia Pacific-focused leadership roles with responsibilities spanning Manufacturing and Operations, Strategic Marketing, Project Management, Product Management and Research & Development.
He joined ResMed in Sydney as a Design Engineer in 1999 and holds a number of patents granted worldwide. Prior to ResMed, Mr. Price held product development roles at home appliances manufacturer, Sunbeam, and Aristocrat Leisure Industries, one of the world’s leading providers of gaming solutions.
Mr. Price graduated from the Advanced Management Program (AMP) at INSEAD International Business School, Singapore, in 2013. He holds a bachelor’s degree, with honors, in Industrial Design from the University of Technology, Sydney, and is a Lean Six Sigma Green Belt.
In his role as ResMed’s Chief Strategy Officer, Hemanth has responsibility for the company’s corporate strategy and corporate development functions globally. He also serves as a member of the CEO Ops Team. Prior to joining ResMed in September 2013, Hemanth was strategy consultant for 14 years, with a focus on growth strategies across consumer products, high tech, biotech and other industries. He advised on a range of issues including corporate strategy, business unit strategy, portfolio strategy, and inorganic growth strategy.
He was most recently a Principal with Monitor Deloitte, Deloitte Consulting’s Strategy practice, and co-led their San Francisco office. Prior to Deloitte, Hemanth was a Partner with Monitor Group where he co-led Corporate Finance activities in North America and shared leadership responsibility for Monitor’s M&A advisory practice. Prior to Monitor Group, Hemanth was an investment banker with Donaldson, Lufkin and Jenrette in New York, where he advised clients in structuring and executing debt and equity offerings, as well as private equity transactions.
He holds an MBA in Finance, Strategy and Marketing from the Kellogg School of Management and a BS in Computer Science from Cornell University’s College of Engineering.